Viking Therapeutics Shares Jump 1.75% to 2025 High on Strong Phase II Trial Results

The share price rose to its highest level so far this month, with an intraday gain of 1.75% on Nov. 6, reaching a 2025 high. The move followed positive developments in Viking Therapeutics’ obesity drug pipeline, particularly robust Phase 2 trial results for its dual GLP-1/GIP agonist VK2735, which demonstrated significant improvements in prediabetes reversal and metabolic syndrome reduction. The stock’s performance reflects investor optimism about the drug’s potential to address unmet needs in the growing metabolic disorder market.

Viking’s Phase 2 VENTURE trial showed 78% of patients with prediabetes normalized glycemic status after 13 weeks of VK2735 treatment, compared to 29% in the placebo group. Additionally, 68% of patients met criteria for metabolic syndrome reversal, while mean weight loss reached 14.7%. These outcomes, coupled with a favorable safety profile, position VK2735 as a competitive candidate in a sector dominated by single-agonist therapies. The company is advancing the drug into Phase 3 trials under the VANQUISH-1 study, with enrollment progressing ahead of schedule and projected completion by early 2026.

Analysts have raised price targets following the data, with Canaccord Genuity and BTIG setting estimates above $100. Viking’s market cap of $4.1 billion reflects its strong cash position and focus on late-stage development, despite ongoing losses. However, risks remain, including regulatory hurdles and competition from established players. The stock’s near-term trajectory may hinge on upcoming data presentations at ObesityWeek 2025 and the American Heart Association Scientific Sessions, which could further validate its therapeutic potential and attract investor interest.